
Soleno Therapeutics (SLNO) Stock Forecast & Price Target
Soleno Therapeutics (SLNO) Analyst Ratings
Bulls say
Soleno Therapeutics is set to be acquired at a premium of 34% to its current share price, driven by its FDA-approved product VYKAT XR which has shown strong early adoption and is expected to generate peak annual sales of $2.3B in the U.S. by 2034. The transaction is fully funded and expected to close swiftly without financing contingencies, underscoring the company's healthy financial position and potential for value maximization through M&A or licensing activities. The recent estimates have been updated to reflect higher revenue and earnings projections, further solidifying the positive outlook for Soleno Therapeutics.
Bears say
Soleno Therapeutics is facing significant risks, including regulatory issues that could hinder the completion of its acquisition and fail to secure approval for its product DCCR in Europe. Valuation based on a discounted cash flow approach and an effective tax rate of 29.84% yields a total firm value of $6.23B and a 12-month price objective of $120 per share. Additional risks to consider are the potential for slow uptake of VYKAT XR in the US market, generic erosion of its franchise, and dilution risk in the long term.
This aggregate rating is based on analysts' research of Soleno Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Soleno Therapeutics (SLNO) Analyst Forecast & Price Prediction
Start investing in Soleno Therapeutics (SLNO)
Order type
Buy in
Order amount
Est. shares
0 shares